BPC157，TB4 10mg+10mg（Blend）

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a naturally occurring bioactive peptide isolated and purified from human gastric mucosal protein extract. Composed of 15 amino acids, it constitutes an active fragment of endogenous gastroprotective peptides. Its stable structure exhibits resistance to gastric acid and enzymatic degradation. It maintains bioactivity not only through injection but also when administered orally, requiring no complex formulation modifications to exert its effects. It is currently one of the most extensively studied peptide molecules for tissue repair and protection.

BPC-157 promotes tissue regeneration and repair by activating fibroblast proliferation, accelerating collagen synthesis, and inducing angiogenesis to restore damaged connective tissues such as muscles, tendons, ligaments, and skin. It also modulates extracellular matrix metabolism to reduce scar tissue formation. It exhibits anti-inflammatory and immunomodulatory effects by suppressing pro-inflammatory factor release (e.g., TNF-α, IL-6), reducing inflammatory response intensity, and alleviating tissue edema and pain. It provides visceral protection, particularly offering potent defense for digestive mucosa (stomach, intestines) by enhancing mucosal barrier integrity and reducing damage from gastric acid or medications. It also protects organs like the liver and kidneys, mitigating oxidative stress and toxin-induced damage.

It can be used as an adjunct therapy for sports injuries such as tendinitis, muscle strains, and ligament tears, shortening recovery time and reducing the duration of impaired athletic performance. In gastrointestinal disease management, it addresses conditions like gastric ulcers, duodenal ulcers, and inflammatory bowel diseases (e.g., Crohn's disease) by protecting the mucosa, promoting mucosal repair, and alleviating abdominal pain and slow ulcer healing. In organ protection and repair research, it serves as an adjunctive intervention to mitigate drug-induced liver injury and chemical nephrotoxicity, while also demonstrating efficacy in repairing nerve damage (e.g., peripheral nerve contusions).

What is TB4?

TB4 (Thymosin Beta-4) is an endogenous peptide composed of 43 amino acids, derived from the core active region of naturally occurring human thymosin β4. It exhibits excellent water solubility and structural stability, naturally occurring widely in tissues like blood, muscle, and skin, and can be obtained through synthetic methods. Compared to intact thymosin β4, TB4 retains key biological activity while being more readily absorbed by tissues via injection. It functions without requiring complex modifications, making it one of the most extensively studied peptide molecules in the field of tissue repair.

TB4 promotes cell migration and tissue regeneration by activating the migratory capacity of repair-related cells such as endothelial cells and fibroblasts. It accelerates angiogenesis and collagen deposition, aiding in the repair of connective tissue injuries in muscles, tendons, ligaments, and skin. Simultaneously, it regulates extracellular matrix balance to reduce excessive scar formation. It exhibits anti-inflammatory and cytoprotective effects by inhibiting the release of pro-inflammatory factors like TNF-α and IL-1β, thereby reducing tissue inflammation and edema. Furthermore, it enhances cellular antioxidant stress resistance, mitigating damage from ischemia and toxins, and plays a crucial role in stabilizing the microenvironment of injured tissues.

It is used as an adjunct therapy for sports-related injuries such as muscle strains, tendinitis, and ligament tears, shortening the healing cycle and aiding in the restoration of athletic function. In wound healing, it accelerates closure of chronic non-healing wounds (e.g., diabetic foot ulcers) and burn injuries by promoting granulation tissue growth and epithelial cell migration. In tissue damage interventions, it also demonstrates efficacy in nerve injury (e.g., peripheral nerve contusion) and post-myocardial ischemia repair studies.

Conclusion

The BPC-157/TB4 Blend is a composite system comprising two endogenous peptides with tissue repair activity. BPC-157, derived from human gastric mucosal protein, contains 15 amino acids, while TB4 is an active fragment of thymosin β4, comprising 43 amino acids. When combined, they exert synergistic effects. BPC-157 promotes fibroblast proliferation, enhances mucosal barrier integrity, and suppresses pro-inflammatory factor release, while TB4 regulates actin polymerization, accelerates cell migration, and stimulates angiogenesis. Together, they enhance tissue regeneration and repair efficiency, with additional anti-inflammatory effects, visceral organ protection, and improvement of the cellular microenvironment. Current application research focuses on sports injury recovery (e.g., tendinitis, muscle strains, ligament injuries); gastrointestinal mucosal protection (e.g., gastric ulcer, inflammatory bowel disease adjunctive intervention); and multi-tissue damage synergistic restoration (e.g., skin wounds, minor visceral injuries). This complementary mechanism shortens repair cycles, reduces inflammatory responses, and facilitates intervention in tissue damage-related issues.

About The Author

The above-mentioned materials are all researched, edited and compiled by Corevia Peptides.